MCID: BRS049
MIFTS: 31

Breast Carcinoma in Situ

Categories: Cancer diseases, Genetic diseases, Rare diseases, Reproductive diseases

Aliases & Classifications for Breast Carcinoma in Situ

MalaCards integrated aliases for Breast Carcinoma in Situ:

Name: Breast Carcinoma in Situ 12 14
Non-Infiltrating Carcinoma of Breast 12
Carcinoma in Situ of Breast 12

Classifications:



External Ids:

Disease Ontology 12 DOID:8791
ICD10 33 D05 D05.9
ICD9CM 35 233.0
NCIt 47 C3641
SNOMED-CT 64 154636004 189336000
UMLS 69 C0154084

Summaries for Breast Carcinoma in Situ

MalaCards based summary : Breast Carcinoma in Situ, also known as non-infiltrating carcinoma of breast, is related to lobular neoplasia and ductal carcinoma in situ. An important gene associated with Breast Carcinoma in Situ is ERBB2 (Erb-B2 Receptor Tyrosine Kinase 2). The drugs Anastrozole and Tamoxifen have been mentioned in the context of this disorder. Affiliated tissues include breast, skin and lymph node.

Related Diseases for Breast Carcinoma in Situ

Diseases in the Breast Cancer family:

Breast Benign Neoplasm Inflammatory Breast Carcinoma
Sporadic Breast Cancer Breast Carcinoma in Situ
Brip1-Related Breast Cancer

Diseases related to Breast Carcinoma in Situ via text searches within MalaCards or GeneCards Suite gene sharing:

id Related Disease Score Top Affiliating Genes
1 lobular neoplasia 10.2
2 ductal carcinoma in situ 10.1
3 breast cancer 9.9
4 hypoxia 9.6

Symptoms & Phenotypes for Breast Carcinoma in Situ

Drugs & Therapeutics for Breast Carcinoma in Situ

Drugs for Breast Carcinoma in Situ (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 234)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Anastrozole Approved, Investigational Phase 4,Phase 3,Phase 2 120511-73-1 2187
2
Tamoxifen Approved Phase 4,Phase 3,Phase 2,Phase 1 10540-29-1 2733526
3
Letrozole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 112809-51-5 3902
4
Exemestane Approved, Investigational Phase 4,Phase 3,Phase 2 107868-30-4 60198
5
Toremifene Approved, Investigational Phase 4 89778-26-7 3005573
6 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1
7 Aromatase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
8 Bone Density Conservation Agents Phase 4,Phase 3,Phase 2,Phase 1
9 Estrogen Antagonists Phase 4,Phase 3,Phase 2,Phase 1
10 Estrogen Receptor Modulators Phase 4,Phase 3,Phase 2,Phase 1
11 Estrogens Phase 4,Phase 3,Phase 2,Phase 1
12 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
13 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
14 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
15 Selective Estrogen Receptor Modulators Phase 4,Phase 3,Phase 2,Phase 1
16 Steroid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
17 Anticoagulants Phase 4,Phase 3,Phase 2
18 Calcium, Dietary Phase 4,Phase 3,Phase 2,Phase 1
19 Chelating Agents Phase 4,Phase 3,Phase 2
20 Citrate Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1
21
Citric Acid Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 77-92-9 311
22
Estradiol Approved, Investigational, Vet_approved Phase 3,Phase 2 50-28-2 5757
23
Cyclophosphamide Approved, Investigational Phase 3,Phase 2 50-18-0, 6055-19-2 2907
24
Epirubicin Approved Phase 3,Phase 2 56420-45-2 41867
25
Fluorouracil Approved Phase 3,Phase 2 51-21-8 3385
26
Carboplatin Approved Phase 3,Phase 2 41575-94-4 10339178 498142 38904
27
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
28
Trastuzumab Approved, Investigational Phase 3,Phase 2,Phase 1 180288-69-1 9903
29
Paclitaxel Approved, Vet_approved Phase 3,Phase 2 33069-62-4 36314
30
Progesterone Approved, Vet_approved Phase 3,Phase 2,Early Phase 1 57-83-0 5994
31
Medroxyprogesterone acetate Approved, Investigational Phase 3 71-58-9
32
Norethindrone Approved Phase 3 68-22-4 6230
33
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
34
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
35
Metformin Approved Phase 3,Phase 1,Early Phase 1 657-24-9 14219 4091
36
Oxybutynin Approved, Investigational Phase 3 5633-20-5 4634
37
Pembrolizumab Approved Phase 3,Phase 2,Early Phase 1 1374853-91-4
38
Adenosine Approved, Investigational Phase 3 58-61-7 60961
39
Pertuzumab Approved Phase 3,Phase 1,Phase 2 145040-37-5, 380610-27-5 2540
40
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
41
leucovorin Approved, Nutraceutical Phase 3 58-05-9 143 6006
42
Cholecalciferol Approved, Nutraceutical Phase 3,Phase 1,Phase 2 67-97-0 6221 10883523 5280795
43
Ergocalciferol Approved, Nutraceutical Phase 3,Phase 1,Phase 2 50-14-6 5280793
44
Vitamin D Approved, Nutraceutical, Vet_approved Phase 3,Phase 1,Phase 2 1406-16-2
45
Docetaxel Approved May 1996, Investigational Phase 3,Phase 2,Phase 1 114977-28-5 148124 9877265
46
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
47 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
48 Estradiol 17 beta-cypionate Phase 3,Phase 2
49 Estradiol 3-benzoate Phase 3,Phase 2
50 Estradiol valerate Phase 3,Phase 2 979-32-8

Interventional clinical trials:

(show top 50) (show all 308)

id Name Status NCT ID Phase Drugs
1 Phase IV Trial to Evaluate Breast Brachytherapy Using the Mammosite-Ml® Completed NCT01448447 Phase 4
2 Electronic Xoft Intersociety Brachytherapy Trial: Electronic Brachytherapy (EBT) For Treatment of Early Stage Breast Cancer Completed NCT00742222 Phase 4
3 Endocrine Therapy in Treating Patients With HER2 Negative, Low Risk Breast Cancer Not yet recruiting NCT03238703 Phase 4 Anastrozole;Exemestane;Letrozole;Tamoxifen Citrate;Toremifene Citrate
4 Suction Drain Versus the Use of Adaptive Skin Sutures After Mastectomy ± Axillary Lymphadenectomy; a Prospective Randomised Study Unknown status NCT01509781 Phase 3
5 Spect Analysis of Cardiac Perfusion Changes After Whole Breast/Chest Wall Radiation Therapy With Active Breathing Coordinator Unknown status NCT00321048 Phase 3
6 Anastrozole or Tamoxifen in Treating Postmenopausal Women With Ductal Carcinoma in Situ Who Are Undergoing Lumpectomy and Radiation Therapy Completed NCT00053898 Phase 3 anastrozole;tamoxifen citrate
7 Evaluation of the Diagnostic Performance of MRI±Biopsy to Optimize Resection of Ductal Carcinoma In Situ (DCIS) Breast Cancer Completed NCT01112254 Phase 3
8 Genetic Counseling or Usual Care in Helping Women With Newly Diagnosed Ductal Carcinoma In Situ or Stage I, Stage II, or Stage IIIA Breast Cancer Make Treatment Decisions Completed NCT00262899 Phase 3
9 Mometasone Furoate in Preventing Radiation Dermatitis in Patients Undergoing Radiation Therapy to the Breast or Chest Wall for Invasive Breast Cancer or Ductal Carcinoma in Situ Completed NCT00438659 Phase 3 mometasone furoate
10 S9630, Medroxyprogesterone in Treating Women With Breast Cancer Completed NCT00002920 Phase 3 medroxyprogesterone;tamoxifen citrate
11 Hormone Replacement Therapy for Hot Flashes and/or Vaginal Symptoms in Postmenopausal Women Receiving Tamoxifen for Breast Cancer Completed NCT00026286 Phase 3 conjugated estrogens;medroxyprogesterone
12 Intraoperative Gamma Camera for Breast Cancer Surgery Completed NCT00757302 Phase 3
13 Hormone Replacement Therapy and the Risk of Breast Cancer Recurrence in Women With Previous Early Stage Breast Cancer Completed NCT00003771 Phase 3 norethindrone acetate
14 Study of Docetaxel in Breast Cancer Patients Completed NCT00174707 Phase 3 epidoxorubicine, ciclophosphamide, methotrexate, fluorouracile;epidoxorubicine, docetaxel, ciclophosphamide, methotrexate, fluorouracile;epidoxorubicine, docetaxel, cyclophosphamide
15 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
16 "The Efficacy of 'Radioguided Occult Lesion Localization' (ROLL) Versus 'Wire-guided Localization' (WGL) in Breast Conserving Surgery for Non-palpable Breast Cancer: a Randomized Clinical Trial" Completed NCT00539474 Phase 3
17 Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer Completed NCT00021255 Phase 3 Doxorubicin;Cyclophosphamide;Docetaxel;Herceptin;Carboplatin
18 Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal Women Completed NCT00003906 Phase 3 Raloxifene;Tamoxifen
19 Metformin Hydrochloride in Preventing Breast Cancer in Patients With Atypical Hyperplasia or In Situ Breast Cancer Recruiting NCT01905046 Phase 3 metformin hydrochloride
20 Oxybutynin Chloride in Managing Hot Flashes Recruiting NCT02961790 Phase 3 Oxybutynin Chloride
21 Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer Recruiting NCT01272037 Phase 3 Anastrozole;Exemestane;Letrozole;Systemic Chemotherapy;Tamoxifen Citrate
22 Pembrolizumab in Treating Patients With Triple-Negative Breast Cancer Recruiting NCT02954874 Phase 3
23 Therapeutic Nipple Sparing Mastectomy. Recruiting NCT02311959 Phase 3
24 Management of Low-risk DCIS Recruiting NCT02492607 Phase 3
25 Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522) Recruiting NCT03036488 Phase 3 Carboplatin;Paclitaxel;Doxorubicin;Epirubicin;Cyclophosphamide;Placebo
26 Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy Active, not recruiting NCT00769379 Phase 3
27 Adjuvant Tamoxifen Compared With Anastrozole in Treating Postmenopausal Women With Ductal Carcinoma In Situ Active, not recruiting NCT00072462 Phase 3 tamoxifen citrate;Anastrozole
28 Breast-Conserving Surgery and Whole-Breast Radiation Therapy With or Without Additional Radiation Therapy to the Tumor in Treating Women With Ductal Carcinoma in Situ (BONBIS) Active, not recruiting NCT00907868 Phase 3
29 Radiation Therapy With or Without Optional Tamoxifen in Treating Women With Ductal Carcinoma in Situ Active, not recruiting NCT00003857 Phase 3 tamoxifen citrate
30 RAPID: Randomized Trial of Accelerated Partial Breast Irradiation Active, not recruiting NCT00282035 Phase 3
31 APBI Versus EBRT Therapy After Breast Conserving Surgery for Low-risk Breast Cancer Active, not recruiting NCT00402519 Phase 3
32 Radiation Doses and Fractionation Schedules in Non-low Risk Ductal Carcinoma In Situ (DCIS) of the Breast Active, not recruiting NCT00470236 Phase 3
33 Trial of Low Dose Tamoxifen in Women With Breast Intraepithelial Neoplasia Active, not recruiting NCT01357772 Phase 3 Tamoxifen;placebo
34 Letrozole or Tamoxifen in Treating Postmenopausal Women With Breast Cancer Active, not recruiting NCT00004205 Phase 3 letrozole;tamoxifen citrate
35 Higher Per Daily Treatment-Dose Radiation Therapy or Standard Per Daily Treatment Radiation Therapy in Treating Patients With Early-Stage Breast Cancer That Was Removed by Surgery Active, not recruiting NCT01349322 Phase 3
36 Randomized Controlled Trial of Neo-adjuvant Progesterone and Vitamin D3 in Women With Large Operable Breast Cancer and Locally Advanced Breast Cancer Active, not recruiting NCT01608451 Phase 3 Cholecalciferol;Inj. Progesterone
37 Letrozole in Preventing Breast Cancer in Postmenopausal Women With a BRCA1 or BRCA2 Mutation Active, not recruiting NCT00673335 Phase 3 letrozole;Placebo
38 Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer Active, not recruiting NCT00878709 Phase 3 neratinib
39 Exemestane in Preventing Cancer in Postmenopausal Women at Increased Risk of Developing Breast Cancer Active, not recruiting NCT00083174 Phase 3 exemestane
40 A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE) Active, not recruiting NCT01772472 Phase 3 trastuzumab;trastuzumab emtansine
41 A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer Active, not recruiting NCT01358877 Phase 3 5-Fluorouracil;Carboplatin;Cyclophosphamide;Docetaxel;Doxorubicin;Epirubicin;Paclitaxel;Pertuzumab;Placebo;Trastuzumab
42 Risedronate in Improving Bone Mineral Density and Bone Health in Postmenopausal Women With Ductal Carcinoma In Situ Enrolled in Clinical Trial CRUK-IBIS-II-DCIS Withdrawn NCT00324714 Phase 3 risedronate sodium
43 Adjuvant Radiation Therapy Compared With Observation After Surgery in Treating Women With Estrogen Receptor Positive or Progesterone Receptor Positive Ductal Carcinoma In Situ of the Breast Who Are Receiving Tamoxifen or Anastrozole Unknown status NCT00077168 Phase 2 anastrozole;tamoxifen citrate
44 Tamoxifen in Preventing Breast Cancer in Women at Increased Risk for Breast Cancer Unknown status NCT00096369 Phase 2 tamoxifen citrate
45 Effect of Omega 3 on Atrophic Vaginitis in Breast Cancer Survivors Unknown status NCT02150525 Phase 2
46 "Phase II Study of PET Guided Neoadjuvant Chemotherapy (NAC) and Oncotype Guided Hormonal Therapy of Breast Cancer" Unknown status NCT01641406 Phase 2 Docetaxel, Epirubicin, Cyclophosphamide/Navelbine, Capecitabine, Trastuzumab, Bevacizumab;Docetaxel, Epirubicin, Cyclophosphamide/Navelbine, Capecitabine, Trastuzumab, Bevacizumab;Docetaxel, Epirubicin, Cyclophosphamide/Navelbine, Capecitabine, Trastuzumab, Bevacizumab
47 Dose Optimization for Pulsed-dose-rate (PDR)/High-dose-rate (HDR) Brachytherapy Alone for Early Breast Cancer Unknown status NCT01175694 Phase 2
48 Whole Breast Irradiation With Intensity Modulated Radiotherapy and Simultaneously Integrated Boost for Early Stage Breast Cancer Patients Unknown status NCT01394575 Phase 2
49 Study Of Intraductal Carboplatin In Women With Ductal Carcinoma In Situ (DCIS) Unknown status NCT00669747 Phase 2 Carboplatin i.d. Days 1 & 15;Carboplatin i.d. Day 1; Normal Saline i.d. Day 15;Normal Saline
50 Cisplatin-monotherapy in the Treatment of BRCA1 Positive Breast Cancer Patients in Poland Unknown status NCT01630226 Phase 2 Neoadjuvant Cisplatin Chemotherapy

Search NIH Clinical Center for Breast Carcinoma in Situ

Genetic Tests for Breast Carcinoma in Situ

Anatomical Context for Breast Carcinoma in Situ

MalaCards organs/tissues related to Breast Carcinoma in Situ:

39
Breast, Skin, Lymph Node, Testes, Bone, Prostate, Liver

Publications for Breast Carcinoma in Situ

Articles related to Breast Carcinoma in Situ:

(show all 45)
id Title Authors Year
1
Ductal Breast Carcinoma In Situ: Mammographic Features and Its Relation to Prognosis and Tumour Biology in a Population Based Cohort. ( 28286675 )
2017
2
Breast carcinoma in situ: An observational study of tumor subtype, treatment and outcomes. ( 27926499 )
2016
3
Mammographic extent of microcalcifications and oestrogen receptor expression affect preoperative breast carcinoma in situ size estimation. ( 27639877 )
2016
4
The prognostic role of HER2 expression in ductal breast carcinoma in situ (DCIS); a population-based cohort study. ( 26062614 )
2015
5
Usefulness and limitations of E-cadherin and I^-catenin in the classification of breast carcinomas in situ with mixed pattern. ( 23837653 )
2013
6
Mondor's disease in a patient previously treated for breast carcinoma in situ: a case report. ( 22595929 )
2012
7
Differences in breast carcinoma in situ between menopausal and premenopausal women. ( 21617240 )
2011
8
Might the widespread use of statin drugs explain the increase in prevalence of breast carcinoma in situ? ( 19896281 )
2010
9
Prevalence of BRCA1 and BRCA2 mutations in women with breast carcinoma In Situ and referred for genetic testing. ( 21149333 )
2010
10
Pregnancy-related factors and the risk of breast carcinoma in situ and invasive breast cancer among postmenopausal women in the California Teachers Study cohort. ( 20565829 )
2010
11
Prevalence of breast carcinoma in situ in the United States. ( 19706857 )
2009
12
The occurrence of invasive cancers following a diagnosis of breast carcinoma in situ. ( 18665169 )
2008
13
OSM, LIF, its receptors, and its relationship with the malignance in human breast carcinoma (in situ and in infiltrative). ( 18317962 )
2008
14
Risk factors for breast carcinoma in situ versus invasive breast cancer in a prospective study of pre- and post-menopausal women. ( 17063272 )
2007
15
An expression signature of syndecan-1 (CD138), E-cadherin and c-met is associated with factors of angiogenesis and lymphangiogenesis in ductal breast carcinoma in situ. ( 17244359 )
2007
16
Oral contraceptive use and risk of breast carcinoma in situ. ( 18006914 )
2007
17
Cigarette smoking and risk of breast carcinoma in situ. ( 17700252 )
2007
18
Molecular classification of breast carcinoma in situ. ( 17375183 )
2006
19
Oral contraceptive use and risk of breast carcinoma in situ (United States). ( 17006721 )
2006
20
Quality of life for women diagnosed with breast carcinoma in situ. ( 17050872 )
2006
21
Expression patterns of angiogenic and lymphangiogenic factors in ductal breast carcinoma in situ. ( 15841074 )
2005
22
Postmenopausal levels of sex hormones and risk of breast carcinoma in situ: results of a prospective study. ( 15540225 )
2005
23
Impact of reproductive factors and lactation on breast carcinoma in situ risk. ( 15054874 )
2004
24
Proliferative lesions of the breast: carcinoma in situ. ( 15022899 )
2003
25
Lifetime recreational exercise activity and risk of breast carcinoma in situ. ( 14601085 )
2003
26
Family history of breast and ovarian cancer and the risk of breast carcinoma in situ. ( 12611452 )
2003
27
Hypoxia promotes a dedifferentiated phenotype in ductal breast carcinoma in situ. ( 12670886 )
2003
28
The risk of a contralateral breast cancer among women diagnosed with ductal and lobular breast carcinoma in situ: data from the Connecticut Tumor Registry. ( 14659121 )
2003
29
Oral contraceptives and the risk of ductal breast carcinoma in situ. ( 14572155 )
2003
30
DNA content and cell number determination in microdissected samples of breast carcinoma in situ. ( 12118344 )
2002
31
Breast carcinoma in situ: risk factors and screening patterns. ( 11734598 )
2001
32
p53 mutations and expression in breast carcinoma in situ. ( 10623666 )
2000
33
Breast carcinoma in situ in a male. Report of a case diagnosed by nipple discharge cytology. ( 9622698 )
1998
34
Time trend of female breast carcinoma in situ by race and histology in Connecticut, USA. ( 9071907 )
1997
35
Biological heterogeneity of breast carcinoma in situ. ( 8651598 )
1996
36
Biophenotypes of breast carcinoma in situ defined by image analysis of biological parameters. ( 8692711 )
1996
37
Male breast carcinoma in situ. Report of a case diagnosed by nipple discharge cytology alone. ( 7654052 )
1995
38
Receptors for estrogen and progesterone in breast carcinoma in situ. ( 1295456 )
1992
39
Breast carcinoma-in-situ: an emerging problem in Singapore. ( 1329232 )
1992
40
Breast carcinoma in situ. ( 20169700 )
1992
41
Ten-year follow-up of breast carcinoma in situ in Connecticut. ( 1365682 )
1992
42
Relationship between c-erbB-2 immunoreactivity and thymidine labelling index in breast carcinoma in situ. ( 1677296 )
1991
43
Breast carcinoma in situ in 167 women--incidence, mode of presentation, therapy and follow-up. ( 1657650 )
1991
44
Breast carcinoma in situ. ( 2535929 )
1989
45
Breast carcinoma in situ. A retrospective review of 112 cases with a minimum 10 year follow-up. ( 2990246 )
1985

Variations for Breast Carcinoma in Situ

Expression for Breast Carcinoma in Situ

Search GEO for disease gene expression data for Breast Carcinoma in Situ.

Pathways for Breast Carcinoma in Situ

GO Terms for Breast Carcinoma in Situ

Sources for Breast Carcinoma in Situ

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....